AKUMS
from 697 today
Akums Drugs and Pharmaceuticals delivered a strong Q1FY27, led by robust momentum in the CDMO vertical and cost discipline, which helped reported margins scale up to a high of 15%. We retain BUY with a higher target price of INR 850.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
